FBIOP supply chain intelligence for Fortress Biotech, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Fortress Biotech, Inc. (FBIOP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ATXI | Avenue Therapeutics, Inc. | 72% | Reciprocal relationship from ATXI graph: product candidates and will rely on third parties to manufacture any products for which we receive regulatory approval and their failure to produce them in th… |
| DERM | Journey Medical Corporation | 72% | racting with third parties for manufacturing, testing, warehousing, distribution, cash collection and related commercial activities; ● we are required by the FDA or a foreign regulatory authority to … |
| DERM | Journey Medical Corporation | 72% | Reciprocal relationship from DERM graph: Reciprocal relationship from FBIOP graph: racting with third parties for manufacturing, testing, warehousing, distribution, cash collection and related commer… |
| MBIO | Mustang Bio, Inc. | 72% | Reciprocal relationship from MBIO graph: n, future events or otherwise . Table of Contents SUMMARY OF RISK FACTORS Our business is subject to risks of which you should be aware before making an i… |
| ORANY | ORANY | 72% | n are insufficient to support a finding of safety and efficacy, FDA may also require additional clinical data or other data and information to address deficiencies in an application. Even if such dat… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from FBIOP graph: n are insufficient to support a finding of safety and efficacy, FDA may also require additional clinical data or ot… |
| TGTX | TG Therapeutics, Inc. | 72% | Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIOP graph: 6 Year ended December 31, 2027 Year ended December 31, 2028 Year ended December 31, 2029 Other Total o… |
| TGTX | TG Therapeutics, Inc. | 72% | 6 Year ended December 31, 2027 Year ended December 31, 2028 Year ended December 31, 2029 Other Total operating lease liabilities Less: present value discount ( ) Net operating lease… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ATXI | Avenue Therapeutics, Inc. | 72% | Contents Our subsidiaries and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product candidates are: Avenue Therapeutics, Inc. (Nasdaq: ATX… |
| ATXI | Avenue Therapeutics, Inc. | 72% | Reciprocal relationship from ATXI graph: Reciprocal relationship from FBIOP graph: Contents Our subsidiaries and partner companies that are pursuing development and/or commercialization of biopharmac… |
| AXSM | Axsome Therapeutics, Inc. | 72% | Zeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“Sentynl”), Axsome Therapeutics, Inc. (“Axsome”), and Sun Pharma. Our subsidiaries an… |
| AXSM | Axsome Therapeutics, Inc. | 72% | Reciprocal relationship from AXSM graph: Reciprocal relationship from FBIOP graph: Zeneca plc as successor-in-interest to Alexion Pharmaceuticals, Inc. (“AstraZeneca”), Sentynl Therapeutics, Inc. (“S… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from FBIOP graph: financings. To date, four partner companies are publicly-traded, and three subsidiaries have consummated strategic pa… |
| AZN | AstraZeneca PLC | 72% | financings. To date, four partner companies are publicly-traded, and three subsidiaries have consummated strategic partnerships with industry leaders, including AstraZeneca plc as successor-in-intere… |
| DERM | Journey Medical Corporation | 72% | racting with third parties for manufacturing, testing, warehousing, distribution, cash collection and related commercial activities; ● we are required by the FDA or a foreign regulatory authority to … |
| DERM | Journey Medical Corporation | 72% | Reciprocal relationship from DERM graph: Reciprocal relationship from FBIOP graph: Reciprocal relationship from DERM graph: Reciprocal relationship from FBIOP graph: Reciprocal relationship from DERM… |
| MBIO | Mustang Bio, Inc. | 72% | Reciprocal relationship from MBIO graph: Item 1. Business OVERVIEW Mustang Bio, Inc. (“Mustang,” “we,” “us,” “our” or the “Company”) is a clinical-stage biopharmaceutical company focused on transla… |
| MBIO | Mustang Bio, Inc. | 72% | Contents Our subsidiaries and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product candidates are: Avenue Therapeutics, Inc. (Nasdaq: ATX… |
| TGTX | TG Therapeutics, Inc. | 72% | Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIOP graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from FBIOP graph: Reciprocal relationship from TGTX… |
| TGTX | TG Therapeutics, Inc. | 72% | 6 Year ended December 31, 2027 Year ended December 31, 2028 Year ended December 31, 2029 Other Total operating lease liabilities Less: present value discount ( ) Net operating lease… |
| XYF | X Financial | 72% | Reciprocal relationship from XYF graph: Reciprocal relationship from FBIOP graph: Reciprocal relationship from XYF graph: Reciprocal relationship from FBIOP graph: f observable inputs and minimize th… |
| XYF | X Financial | 72% | f observable inputs and minimize the use of unobservable inputs when measuring fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| FBIOP-DEBT-9435 | Warrants outstanding: 7 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| FBIOP-DEBT-9436 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2020-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| XYF | X Financial | 100.00 | 1 | ['customer'] |
| MBIO | Mustang Bio, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer'] |
| ATXI | Avenue Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| TGTX | TG Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DERM | Journey Medical Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| CRACU | Crown Reserve Acquisition Corp. I | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| BLNE | Beeline Holdings, Inc. | 50.00 | 2 | |
| BTDR | Bitdeer Technologies Group | 50.00 | 2 | |
| CLAR | Clarus Corporation | 50.00 | 2 | |
| ANTA | Antalpha Platform Holding Compa | 50.00 | 2 | |
| AMBR | Amber International Holding Limited | 50.00 | 2 | |
| CWAN | Clearwater Analytics Holdings, Inc. | 50.00 | 2 | |
| BLX | Banco Latinoamericano de Comercio Exterior, S. A. | 50.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 50.00 | 2 | |
| CNDAW | Concord Acquisition Corp II | 50.00 | 2 | |
| DEO | Diageo plc | 50.00 | 2 | |
| CCAP | Crescent Capital BDC, Inc. | 50.00 | 2 |